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http://dx.doi.org/10.1016/j.jfma.201Background/Purpose: The debate on whether long-acting injectable antipsychotic (LAIA)
medication is superior to oral medication, in preventing rehospitalization of patients with
schizophrenia, remains inconclusive. We compared rehospitalization rates over 3 years
following discharge from an acute admission, in which patients either began using LAIAs regu-
larly for the first time, or continued to use oral antipsychotics.
Methods: A retrospective observational study of 92 inpatients with schizophrenia from a
university-based medical center during 2004e2008. The primary outcome measure is the re-
hospitalization rates between groups, as estimated by Kaplan-Meier survival analysis.
Results: Eighteen of 47 (38.3%) LAIA patients, and 16 of 45 (35.6%) oral medication patients
were rehospitalized (average time to rehospitalization, 378  262 vs. 378  340 days;
pZ 0.997). The estimated cumulative rates of rehospitalization were similar between groups.
The overall odds comparing the LAIA to the oral medication group were 1.085  0.373 (95%ave no conflicts of interest relevant to this article.
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540 C.-C. Liu et al.confidence interval: 0.553e2.13, pZ 0.813). Compared to the oral medication group, the LAIA
group had fewer coded with sufficient previous treatment response (32% vs. 69%, p < 0.001),
more poorly compliant (91% vs. 56%, p < 0.001), and a slightly longer length of stay at index
admission (32.7  11.3vs. 27.6  12.1, p Z 0.04).
Conclusion: Initiating LAIAs during admission for an acute psychotic episode, to a group of pa-
tients with an inadequate previous treatment response and poorer compliance, might keep
their rehospitalization rates to the level of their oral antipsychotic medication treated coun-
terparts.
Copyright ª 2013, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
In the treatment of schizophrenia, adherence to a pre-
scribed medication regimen continues to be a problem, as
is often seen when treating other chronic disorders phar-
macologically.1,2 Despite a relatively good initial treatment
response for the first episode of psychosis, the discontinu-
ation rate is generally high,3,4 with both patients and their
key caregivers being inclined to discontinue medication
when symptoms improved. However, the risk of relapse was
around four to five times higher in those who discontinued
treatment.5 A recent randomized control trial showed that
among patients who remitted from their first episode of
psychosis, relapse occurred in 79% of those who were
treated with placebo for 1 year.6 Another observational
study revealed an astonishingly high relapse rate after
discontinuing long-acting injectable antipsychotic treat-
ment for remitted first episode schizophrenia.7 In another
two first-episode studies, resuming medication upon the
first signs of relapse (a targeted maintenance or intermit-
tent treatment strategy) still doubled the risk of relapse
compared to continuous antipsychotic treatment.8,9
It seems obvious that maintenance of antipsychotic
therapy should be the mainstay of relapse prevention for
patients with schizophrenia, but many factors affect
medication adherence, such as cognitive impairment, sub-
stance use, depressive symptoms, adverse effects, incon-
venient medication regimen, feelings of being stigmatized,
and prejudiced attitude and beliefs in an illness model.2,10
A patient’s attitude to medication compliance is more
likely to improve, once their acute symptoms have sub-
sided,11 but sometimes a satisfactory response will not be
obtained until medications have been used regularly for an
extended period. Long-acting injectable antipsychotic
(LAIA) agents were developed to ensure the continuation of
treatment, with the aim of improving the patient’s out-
comes, in both acute and outpatient management.12e14
LAIAs have been demonstrated to help patients in
achieving remission15,16; hence, we were able to reshape
the patient’s attitudes toward treatment in a remitted
state by initiating LAIAs in an acute state.17
However, the apparent advantage of this formulation
was not translated into a wide application of LAIAs, a fact
often related to the psychiatrist’s negative attitudes to-
ward conventional depot antipsychotics,18,19 despite the
patient’s positive attitude.20 Thus, the traditional depots of
antipsychotics are generally reserved for chronic non-
compliant patients.21 Besides, the advantage of LAIAs
over oral antipsychotics has not yet been shown to beconclusive. Haddad et al’s review of the first-generation
depot studies seemed to suggest favorable outcomes over
oral antipsychotics, but the authors also pointed out this
finding being subject to criticism over methodological is-
sues.22 A recent meta-analysis demonstrated an apparent
advantage of LAIAs in reducing relapse rates, but not in
preventing rehospitalization.23 However, a large-scale
randomized trial revealed no significant difference in hos-
pitalization rates between patients using LAIAs and oral
medications.24
In this study, we aimed to explore whether introducing
regular use of LAIAs for patients with schizophrenia, the
first time in their course of illness during admission for an
acute episode, could substantially lower the risk of reho-
spitalization in the following 3 years, as compared to that
of continued administration of oral antipsychotics at index
admission.
Methods
This is a retrospective observational study conducted by
reviewing patients’ medical records. The study protocol has
been approved by the Institutional Review Board of the
study hospital.
Study samples
The researchers examined registration records regarding
the diagnosis of all inpatients admitted to the psychiatric
acute ward of a university-based medical center, between
2004 and 2008. The LAIAs group was defined by patients
with an ICD-9-CM diagnosis of schizophrenia or schizo-
affective disorder, who had not previously received more
than three consecutive doses of LAIAs, in whom regular
LAIA treatment was initiated during index admission for the
first time in the course of their illness. These patients might
have received only one or two injections during admission,
while continuing LAIA therapy during outpatient visits
immediately after discharge.
For comparison, an age- and sex-matched inpatient
admitted in the same month as the index case, was iden-
tified using the following criteria: patients who also have
not previously received more than three consecutive LAIA
doses, and who continued to receive oral antipsychotic
medications throughout index admission. If we failed to find
an appropriate patient for comparison in that month, we
tried to find one in the adjacent 2 months, so that we could
find comparable numbers of patients treated under similar
Long-acting injectable antipsychotic and readmission 541conditions with regard to the clinician’s judgment and
clinical care.
We excluded patients who had been treated with an
LAIA for more than three consecutive doses, were admitted
for their first episode of psychosis via emergency services
with no previous outpatient visit records, had an autistic
spectrum disorder or co-morbid organic mental disorder,
were active substance users, were transferred to the hos-
pital for the treatment of refractory or complicated psy-
chiatric problems, were admitted for treating a co-morbid
physical illness, were transferred to a sub-acute or a
chronic care unit immediately after index admission, or did
not show any records regarding their course of illness
following discharge from index admission. Both LAIA and
oral medication groups might have received intermittent
treatment by antipsychotic depots prior to the index
admission, but they have never used them regularly; by our
definition, receiving three or more consecutive doses.
The initiation of LAIAs is based on the clinician’s clinical
judgment and discussion with patients and their key care-
givers. During the study period, the attending psychiatrists
(CCL, MHH, CML, YLC and TJH) were more likely to recom-
mend LAIAs for those patients whowere hospitalized due to a
non-adherence related relapse, had no history of adequate
treatment to show a favorable clinical response, or were
considered likely to be nonadherent after discharge. The
choice of different LAIAs and the dosage and dosing schedule
is theattendingpsychiatrist’s decision.Therewere threeLAIA
agents, including two conventional depots, fluphenazine
decanoate (Flucan Injection, 25 mg/amp) and flupentixol
decanoate (Fluanxol Depot, 20 mg/amp) and a second-
generation antipsychotic, risperidone long-acting injectable
(RLAI, Risperdal Consta suspension for injection, 25mg/vial),
available at the study hospital. As RLAI is considerably more
expensive than the other two agents, during the investigation
period it was generally reserved for those who had demon-
strated obvious adverse reactions to first-generation anti-
psychotics, or for those who had previously refused regular
use of oral antipsychotics, mainly due to concern of adverse
reactions, particularly extrapyramidal symptoms.Study procedures
The researchers identified eligible LAIA cases and oral
medication patients, based on the above-mentioned
criteria, and reviewed their records to extract informa-
tion using a standardized coding sheet. All subjects’ de-
mographic and clinical profile, including age, sex, duration
of illness, number of previous admissions, whether they had
at least three regular outpatient visits prior to index
admission, if any documented poor compliance to medi-
cation, if any documented history of adequate treatment
revealing a favorable response or not, and length of stay at
index admission, were coded. For the LAIA group, we also
recorded the type of LAIA, time of initiation at index
admission, and number of doses received during admission.
We extracted follow-up data for 3 years, with our primary
outcome being incidence of rehospitalization. For those
who did not show up after some point during follow-up, yet
were not confirmed to be rehospitalized by then, their
time-to-event was censored at the date of their lastoutpatient visit. For those who were not rehospitalized
during the 3 year follow-up, their time-to-event was
censored at day 1095. For any questionable data coding,
such as previous compliance to medication and prior
treatment response, a consensus was made among coders
and the principal investigator (CCL).
Statistical analyses
We compared categorical variables using c2 tests and
examined differences in continuous variables between
groups using t tests, to compare their baseline values and
readmission rates for each year. A 2-sided p value 0.05
was considered to be statistically significant. The relative
risks of readmission were examined by survival analysis,
using the time-to-readmission as the variable of interest.
The survival function and cumulative rehospitalization




In total, we identified 47 patients with schizophrenia or
schizoaffective disorder who initiated therapy with an LAIA
during their admission for an acute episode, and received
more than three consecutive doses the first time during their
course of illness. Among them, 19 (40%) were men, and the
overall mean age was 37.8  10.5 years. The average age at
onset was 27.4  9.4 years, and the average duration of
illness was 10.3  7.8 years. The index admission was, on an
average, 2.98  1.88 times of hospitalization for their
illness. Twenty-four (51%) had made at least three consec-
utive outpatient visits prior to this admission. The majority
(91%) were recorded as having poor compliance or lack of
evidence regarding a sufficient response to previous treat-
ment (68%). Flupentixol decanoate was administered to 20
(43%) patients, RLAI to 15 (32%) patients, and fluphenazine
decanoate to 12 (25%) patients. On average, they received
3.3  1.7 injections during index admission; 26 (55%)
received the first injection within the first 7 days of admis-
sion, and 28 (60%) had received at least three doses before
discharge, including 13 (28%) patients who received more
than four injections during inpatient care.
Comparison of clinical variables between LAIA and
oral medication groups
The oral medication group comprised 45 patients, age and
sex matched to the LAIA group (Table 1). These patients
also had a similar age at onset, duration of illness, number
of hospitalizations, and at least three regular outpatient
visits prior to this admission. While the oral medication
group had significantly more patients with sufficient evi-
dence of treatment response (69% vs. 32%, p < 0.001),
fewer were coded as poorly compliant (56% vs. 91%,
p < 0.001), and this group had a slightly shorter length of
stay at index admission (27.6  12.1 vs. 32.7  11.3,
p Z 0.04) compared to the LAIA group.
Table 1 Demographic and clinical profiles of study participants.
LAIA group (n Z 47) Oral medication
group (n Z 45)
p
Age (y)a 37.8 (10.5) 37.4 (12.4) 0.865
Sex (male) 19 (40%) 23 (51%) 0.216
Age of onset (y)a 27.4 (9.4) 25.6 (10.7) 0.381
Duration of illness (y)a 10.3 (7.8) 11.4 (8.3) 0.519
Number of previous hospitalizationsa 2.98 (1.88) 3.49 (2.58) 0.280
Diagnosis of schizophrenia 44 (94%) 39 (87%) 0.262
3 regular outpatient visits prior to index admission 24 (51%) 26 (58%) 0.518
Inadequate evidence of treatment response 32 (68%) 14 (31%) <0.001
Poor compliance 43 (91%) 25 (56%) <0.001
Length of staya (days) 32.7 (11.3) 27.6 (12.1) 0.04
Crude readmission rate
by the end of 1 y 9 (19%) 10 (22%) 0.716
by the end of 2 y 17 (36%) 12 (27%) 0.327
by the end of 3 y 18 (38%) 16 (36%) 0.785
Average length to rehospitalizationa (days) 378.2  261.8 (n Z 18) 377.8  340.4 (n Z 16) 0.997
Average follow-up days for non-rehospitalized patientsa 893.9  322.6 (n Z 29) 909.3  363.4 (n Z 29) 0.867
Number of dropouts before rehospitalization/censor 12 (25%) 9 (20%) 0.527
LAIA formula
Risperidone LAI 15 (32%)
Flupentixol decanoate 20 (43%)
Fluphenazine decanoate 12 (25%)
LAIA Z long-acting injectable antipsychotic.




























Days after discharge from the index admission
Group = oral antipsychotic Group = LAIA
Kaplan-Meier survival estimates
Figure 1 Kaplan-Meier survival estimates of the proportion
of patients who remained free from rehospitalization during
the follow-up period. Solid line represents the long-acting
injectable antipsychotic (LAIA) treatment group (n Z 47) and
dashed line represents the oral medication group (n Z 45).
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groups
Combining both groups, the crude overall readmission rates
for the 1st, 2nd, and 3rd years were 20.1%, 31.5%, and 37%,
respectively, with no significant difference between the
two groups. The time to rehospitalization of the 18 LAIA
patients ranged from 14 to 935 days, with a mean  SD of
378  262 days, while that of the 16 oral medication pa-
tients ranged from 37 to 1092 days (378  340 days). The
average length of follow-up of the 29 non-rehospitalized
LAIA patients was 894  333 days, while that of the 29
oral medication patients was 909  363 days. The dropout
rates during follow-up were similar in both groups (25% vs.
20%, p Z 0.527).
The Kaplan-Meier estimation of survival function
revealed the cumulative  SE rates of rehospitalization at
1, 2, and 3 years for the LAIA group to be 17.8%  5.7%,
34%  7.2%, and 42.6%  7.7%, respectively, and for the oral
medication group to be 26.1%  6.8%, 28.7%  7%, and
39.7%  7.8%, respectively, (Fig. 1). The overall odds of
rehospitalization, comparing the LAIA to the oral medica-
tion group during this 3 year follow-up period, were found
to be 1.085  0.373 [95% confidence interval (CI):
0.553w2.13, p Z 0.813], which is not significantly
different.
Comparison of rehospitalization rates among three
LAIAs
For the LAIA patients, the demographic and clinical profiles
between the three long-acting antipsychotic-treatedgroups were not significantly different (data not pre-
sented); neither were there any significant differences in
rehospitalization rates between these three subgroups
(Fig. 2), with five (33%), eight (40%), and five (42%) patients
from the risperidone LAI, flupentixol decanoate, and
fluphenazine decanoate group, respectively, having been





























Days after discharge from the index admission
LAIA = risperidone LAI
LAIA = flupentixol decanoate
LAIA = fluphenazine decanoate
Kaplan-Meier survival estimates
Figure 2 Kaplan-Meier survival estimates of the proportion
of patients treated with long-acting injectable antipsychotics
(LAIAs) who remained free from rehospitalization during the
follow-up period. Patients who received risperidone LAI are
represented by the long-dash line (nZ 15), those who received
flupentixol decanoate are represented by the short-dash line
(n Z 20), and those who received fluphenazine decanoate are
represented by the solid line (n Z 12).
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Our results revealed that initiating LAIAs during admission
for an acute psychotic episode does not yield a significantly
lower readmission rate compared to administering oral
medications. However, rehospitalization is a clinical
outcome related to many factors during the course of
schizophrenic disorder.25 In Taiwan, using the National
Health Insurance (NHI) dataset, it has been estimated that
following discharge from an index hospitalization, 42.5% of
patients with schizophrenia were readmitted within 30
days.26 This figure appears to be an overestimation attrib-
utable to our unique insurance system; a number of hos-
pitals discharge their inpatients after having been admitted
for 30 days, yet readmit those who need continued inpa-
tient care 2 weeks later, as a strategy to cope with insur-
ance regulations, resulting in an inflated readmission rate.
Another Taiwanese study also used the NHI dataset with a
mirror-image method, and demonstrated a significant
decrease in readmission rates and hospital stays over a
treatment span of 6 months,27 whilst the comparison period
is relatively short and this method was subject to selection
bias and the bias of regression to the mean.22 Being a
university-based medical center, our hospital gives rela-
tively less concern to the NHI reimbursement policies.
Additionally, the advantages of using this single-site popu-
lation include less diversity in the standards of hospitali-
zation and a better consistence in practice, compared to a
multisite case study, and we could deliberately exclude
those whose rehospitalizations were not primarily attrib-
utable to antipsychotic medications.
Interpreting from a different perspective, our results
suggest that initiating LAIAs to a specific group of patients,
who were less compliant and have not been effectively
treated previously, might be a plausible strategy to keepthem at a risk level of rehospitalization similar to their oral
antipsychotics-treated counterparts, for up to 3 years. In
our sample, an LAIA is not randomly assigned to an indi-
vidual patient, but is a reflection of the clinician’s judg-
ment based on their knowledge to the patient’s previous
history and a lack of confidence to their patient’s adher-
ence. Thus, the lack of significant difference in rehospi-
talization rates between two groups is likely an example of
“confounding by severity” or “confounding by indication”.
Not only in our study, inpatient staff have been demon-
strated to be able to predict early rehospitalization,28 and
depot medicine is more likely to be given to the most ill and
non-compliant patients.29,30 Thus, some seemingly para-
doxical results may need to be interpreted according to the
context. Mental health professionals knew their patients to
be at a higher risk of relapse, requiring hospitalization, and
attempted to prevent such negative outcomes by using
different treatment strategies; however, the results of
their attempts might not always be desirable. For example,
active treatment through community facilities or referral to
aftercare at discharge, were shown to be associated with
increased, rather than decreased, readmission rates.31,32
The majority of our subjects were chronic patients with
an average duration of illness of around 10 years, and three
separate incidences of hospitalization. We speculate
whether the effect of initiating regular use of LAIAs during
an acute episode was perhaps obscure due to the chronic
nature of the illness. Since RLAI was available for treating
schizophrenic patients with more favorable adverse effect
profiles, some researchers advocated initiating RLAI at an
earlier phase of schizophrenia, within 3 years of onset, or
even at the first episode.33e35 Other second-generation
antipsychotics have also been developed in LAI formula-
tions, and all have showed promising effects.36 The finding
that there was no difference in readmission rates between
the different types of LAIAs used in this study, also suggests
that our choice of LAIA was based on practical consider-
ations balanced between anticipated response, tolerability,
and cost-effectiveness. However, our sample size did not
allow us to test whether those who received LAIAs at an
earlier stage of their illness would achieve a more favorable
outcome, nor could we examine factors likely to affect the
outcome of treatment with different LAIAs.
For studying the effect of LAIAs, a naturalistic observa-
tion study might provide information complementary to
randomized control trials. Still, there are limitations to
address. Statistically, the small sample size does not allow
us to examine the complex relationship among previous
compliance, treatment response, indication of LAIA, and
further rehospitalization. The lack of information regarding
those who dropped out during follow-up from the study
hospital might have resulted in an underestimation of the
readmission rate, although this factor is not likely to have
been biased between the two groups, as the dropout rates
were similar. We did not consider a patient’s initial treat-
ment response at the index admission and compliance after
the index admission, such as crossover of treatment be-
tween groups after discharge (that is, switching from LAIAs
to oral medication or vice versa), duration of continuous
treatment, or poor compliance related to adverse re-
actions, all of which are factors that could affect the
outcome. However, it is difficult to obtain valid information
544 C.-C. Liu et al.on these factors for analysis, as some patients might
receive intermittent LAIA injections, or have irregular
outpatient visits, and records of adverse reactions were
unlikely to be comprehensive or consistent. In addition, the
practice style of this university-based hospital might render
our results less generalizable to other psychiatric service
settings.
This is one of the few studies investigating the effec-
tiveness of administering LAIAs exclusively to inpatients
with schizophrenia by initiating LAIA during an acute
episode. Our results, albeit statistically not significant,
suggest this to be a promising approach for lowering the
odds of rehospitalization, in those patients who potentially
have a higher risk, to a level similar to that of an average
inpatient. A larger sample size and a prospective study
design with more thorough data registration will be helpful
to further clarify its use, and to delineate interactions be-
tween the specific types of medication and the timing of
initiating LAIAs therapy.
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